SECTOR
Zydus Lifesciences’ arm enters into strategic partnership with Braile Biomedica Industria
Apr-19-2025

Zydus Lifesciences’ wholly owned subsidiary -- Zydus MedTech has entered into a strategic partnership with Braile Biomedica Industria, Comercio e Representacoes, (Braile Biomedica) --an innovative cardiovascular device manufacturer based in Brazil - to exclusively commercialize its Transcatheter Aortic Valve Implantation (TAVI) technology across Europe, India, and other select markets.

This agreement marks a significant step in Zydus MedTech’s strategic expansion into the fast-growing interventional cardiology segment. The global TAVI market, currently valued at over $6 billion, continues to witness strong growth driven by the increasing incidence of aortic stenosis and the rising demand for minimally invasive cardiac procedures. 

Zydus MedTech, which is actively building its interventional cardiology portfolio, will introduce Braile Biomedica’s advanced balloon-expandable TAVI system to international markets, leveraging its commercial and regulatory expertise. Braile Biomedica - with a proven track record in cardiovascular innovation, particularly in Latin America - will manufacture and supply the product for these markets. 

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.


  RELATED NEWS >>